The 3rd International Electronic Conference on Biomedicines
Part of the International Electronic Conference on Biomedicines series
12–15 May 2025
Biomarkers, Pharmaceuticals, Therapeutic targets, Precision medicine, Infectious diseases, Neurodegeneration, Cardiovascular diseases, Metabolic diseases, Neuromodulation
- Go to the Sessions
-
- S1. Insulin Resistance or Hyperinsulinemia
- S2. Immunotherapy and Adverse Effects
- S3. Tumor Microenvironment
- S4. Immune System, Tumor Immunology and Autoimmune Disease
- S5. Biomedicine in Cardiovascular Diseases
- S6. Diabetes, Obesity and Metabolic Diseases
- S7. Gene Therapy and Gene Editing
- S8. Rare Diseases
- S9. Molecular Mechanisms of Neurodegeneration
- Event Details
Welcome from the Chairs
Dear colleagues,
It is a great pleasure to welcome you to the 3rd International Electronic Conference on Biomedicines (ECB 2025), which will be held from 12 to 15 May 2025. This electronic conference will be held online at https://sciforum.net/event/ECB2025.
The goal of this conference is to enable scientists to present their latest research in the field of biomedicines and engage in discussions with the scientific community worldwide. Recent advances in biomedical research have provided an advanced insight into the biological background of human disease, setting the groundwork for the development of new therapeutic strategies. This conference aims to connect scientists working on this field of research from across the globe, allowing them to exchange ideas on the discovery and characterization of new therapeutic targets in the era of precise medicine.
The agenda of the conference includes, but is not limited to, the following topics:
S1. Insulin Resistance or Hyperinsulinemia
S2. Immunotherapy and Adverse Effects
S3. Tumor Microenvironment
S4. Immune System, Tumor Immunology and Autoimmune Disease
S5. Biomedicine in Cardiovascular Diseases
S6. Diabetes, Obesity and Metabolic Diseases
S7. Gene Therapy and Gene Editing
S8. Rare Diseases
S9. Molecular Mechanisms of Neurodegeneration
The ECB 2025 will be an online-only event, enabling scientists from all over the world to participate, with a small registration fee, but with no requirement for travel or related expenses. The electronic form of the conference provides a platform for rapid and direct exchanges regarding the latest research findings and novel ideas.
All participants are encouraged to submit an extended full manuscript for potential publication in the Biomedicines journal (ISSN: 2227-9059), with a 20% discount on the publication fee. All submitted papers will undergo MDPI’s standard peer-review procedure.
We look forward to receiving your contributions to this scientific event, and we would like to thank you in advance for your support.
Conference chairs
Prof. Dr. Felipe Fregni
Prof. Dr. Allan Stensballe
Prof. Dr. Georgia Levidou
Prof. Dr. Serafino Fazio
Follow the conference organizer on Social Media
Event Chairs
Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA;
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
Laboratory for Medical Mass Spectrometry, Biomedicine group, Aalborg University, Aalborg, Denmark
Dr. Allan Stensballe is a prominent figure in the fields of proteomics, systems biology, inflammation, biomarker discovery, and omics data analysis. He is associated with Aalborg University's Department of Health Science. Dr. Stensballe's expertise is deeply rooted in proteomics and the application of proteomics for understanding human disease pathology, especially in the context of precision medicine. He has been pivotal in leading the precision health segment of the Translational Biomarkers for Pain and Precision Medicine research group at Aalborg University in Denmark. This initiative aims to bridge the gap between academic research and small to medium-sized enterprises (SMEs) through technology-driven innovation, particularly in crucial areas that impact global health and wellness.
Department of Pathology, Paracelsus Medical University, Klinikum Nuremberg, Germany
Prof. Dr. Georgia Levidou is a consultant Pathologist at the Department of Pathology, Paracelsus medical university in Nuremberg, Germany. She received her medical degree (MD), PhD and MSc in Biostatistics at the University of Athens, Greece. She has a twenty years’ experience on pathology and research acquired in leading research centers and is an author of more than 87 peer-reviewed articles. Her research interests span both cancer diagnostics, cellular and molecular pathology as well as tumor prognostic and therapeutic biomarkers. Prof. Levidou has a special interest in hematopathology and is currently working especially on the field of thymic epithelial tumors.
Retired Professor of Internal Medicine, Federico II University School of Medicine, Naples, Italy
Serafino Fazio MD was born in Naples (ITALY) on February 5,1950. Master’s degree in Medicine and Surgery at the University Federico II of Naples, School of Medicine on December 21,1974. Specialized in Internal Medicine and in Cardiology. He worked first as university researcher and, later, as associated professor of Internal Medicine, at the University Federico II of Naples, School of medicine from July 1975 to July 2012. Now retired. Author of more than 173 papers published on prestigious Journals. Among them: New England Journal of Medicine, Nature medicine, Annals of Internal Medicine, Circulation, International Journal of Cardiology etc. He was particularly interested in the interaction between hormones and heart, heart failure treatment, metabolic syndrome, nutraceutical substances and, recently, in Covid19 treatment. His h-hindex, according to Google scholar is 49.
Session Chairs
Laboratory for Medical Mass Spectrometry, Biomedicine Group, Aalborg University, Aalborg, Denmark
Department of Pathology, Paracelsus Medical University, Klinikum Nuremberg, Germany
Retired Professor of Internal Medicine, Federico II University School of Medicine, Naples, Italy
Department of Life Sciences, European University Cyprus, Nicosia 2404, Cyprus,
School of Infection and Immunity, University of Glasgow, Glasgow G12 8TA, UK
Servicio de Genética, Hospital Universitario Ramóny Cajal - IRYCIS, Madrid, Spain,
Unit 728, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
HUN-REN-SZTE Neuroscience Research Group, Hungarian Research Network, University of Szeged (HUN-REN-SZTE), Szeged, Hungary
Department of Health Sciences, Center for Translational Research on Autoimmune and Allergic Disease-CAAD, Università del
Piemonte Orientale, 28100 Novara, Italy
School of Pharmacy, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China
Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”, Caserta, Italy
genetic dyslipidemias; familial hypercholesterolemia; LDL mutations; lipid metabolism; cardiovascular genetics; PCSK9; cardiomyopathies
Event Committee
Prof. Ubaldo Armato, MD
Section of Maxillofacial Surgery & Odontostomatology Dept. Surgery, Dentistry, Paediatrics & Gynaecology Medical School, University of Verona Verona, Veneto, I-37134 Italy.
tissue engineering; tissue regeneration; skin; vessels; biomaterials; silk fibroin; exosomes; Alzheimer’s disease; astrocytes; neuroinflammation
Prof. Dr. Che-Kun James Shen
1. The PhD Program for Neural Regenerative Medicine, Taipei Medical University, Taipei 115, Taiwan; 2. Institute of Molecular Biology, Academia Sinica, Taipei 115, Taiwan
gene regulation; chromatin; DNA methylation; neurofunction; transcription
Prof. Dr. Celestino Sardu
Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, 80138 Naples, Italy
clinical cardiology; myocardial infarction; cardiovascular genetics; clinical electrophysiology; molecular cardiology
Prof. Dr. Yan-Ru Lou
University of Helsinki, Finland
endocrinology; stem cell; tissue engineering; regenerative medicine; hepatic differentiation; vitamin D
Prof. Dr. Roberto Paganelli
Internal Medicine, UniCamillus, International Medical University in Rome, Italy; (retired) Department of Medicine and Sciences of Aging, University of G. d’Annunzio Chieti and Pescara, Chieti, Italy
immunoglobulins; B and T lymphocyte subpopulations; HIV; cytokines; autoimmunity; allergic diseases; inflammation
Dr. Gianluca Santamaria
1. Department of Experimental and Clinical Medicine, University “Magna Graecia” of Catanzaro, Campus “S. Venuta”, Germaneto, Catanzaro, Italy; 2. Department of Medicine I Molecular Cardiology, Klinikum Rechts der Isar—Technical University Munich, Ismaninger Strasse 22, Munich, Germany
identification and characterization of the molecular and cellular pathophysiological mechanisms associated with the development of lung, endometrial, colon, and ovarian cancer; use of induced pluripotent stem cells as a model for the dissection of the molecular mechanisms governing either the maintenance of pluripotency or cellular transitions during cardiogenesis for the study of congenital heart disease; development of analysis pipelines associated with single-cell next-generation sequencing and integration of biological-omic data
Dr. Amedeo Amedei
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
microbiota-immunity axis; autoimmunity; cancers; inflammation; T cells; micro and nanoplastic effects on human
Dr. Bernard Lebleu
Laboratory of Pathogen Host Interactions, Biology-Health Department, Montpellier University, Montpellier, France
oligonucleotides-based therapeutics; peptide (cell penetrating peptides)-based delivery vectors; antisense oligonucleotides cellular trafficking
Dr. Andrei Surguchov
Department of Neurology, University of Kansas Medical Center, Kansas City, KS 66160, USA
synuclein; neurodegeneration; Parkinson's disease; caveolin; neurodegenerative diseases; SUP35; SUP45
Dr. Cristina Carvalho
Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517, Coimbra, Portugal
Alzheimer’s disease; mitochondrial dysfunction; cell (dys)metabolism; type 2 diabetes
Dr. Pedro A. José
Medicine and Physiology/Pharmacology, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA
hypertension; renal physiology; ion transport; oxidative stress; pharmacogenomics
Dr. Kevin W.-H. Lo
Department of Medicine, University of Connecticut Health Center, Farmington, CT 06030, USA
drug screening, drug delivery; regenerative engineering; signaling transduction
Dr. Donato Liloia
Department of Psychology, University of Turin, Turin, Italy
magnetic resonance imaging; human brain mapping; meta-research; connectomics; brain connectivity; computational neuroscience; Bayesian statistics; fMRI; meta-analysis; clinical trials; DTI; default mode network; Alzheimer’s disease; biological psychiatry; autism; cerebellum; translational neuroimaging
Dr. Yongxiao Wang
Department of Molecular and Cellular Physiology, Albany Meidcal College, Albany, CA, USA
inflammation; reactive oxygen species; cell calcium; ion channels; neurotransmitter receptors; protein kinases
Dr. Michele Ammendola
Department of Health Science, Digestive Surgery Unit, Medical School, University “Magna Graecia”, Viale Europa, Germaneto, 88100 Catanzaro, Italy
surgical oncology; angiogenesis and lymphangiogenesis in gastrointestinal tumor; molecular aspects; traslational reserch in surgery
Dr. Andrea Székely
Department of Anesthesia and Intensive Care, Semmelweis University, Budapest, Hungary
transplantation; cardiac anesthesia; psychosocial factors; frailty
Dr. Arturo Cesaro
Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”, Caserta, Italy
genetic dyslipidemias; familial hypercholesterolemia; LDL mutations; lipid metabolism; cardiovascular genetics; PCSK9; cardiomyopathies
Dr. Bruno M. Fonseca
UCIBIO – Applied Molecular Biosciences Unit, Laboratory of Biochemistry, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira no. 228, 4050-313 Porto, Portugal
pregnancy pathologies; endometrial receptivity; inflammasome; angiogenesis; inflammation; cannabinoids
Prof. Dr. Patrícia C. Pires
Faculty of Pharmacy, University of Coimbra, Portugal
Biomedicines; Cancer; Drug Delivery; Nanomedicines; Pharmaceuticals
Dr. Alessandro Genazzani
Gynecological Endocrinology Center, Department of Obstetrics & Gynecology, Università degli Studi di Modena e Reggio Emilia, Modena, Italy
female reproduction; PCOS; menopause; insulin resistance; stress; functional hypothalamic amenorrhea
Dr. Elisa Belluzzi
1. Musculoskeletal Pathology and Oncology Laboratory, Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, 35129 Padova, Italy.
inflammation; molecular biology; cell biology; osteoarthritis; cartilage; musculoskeletal diseases; bone cancer; synovium; infrapatellar fat pad; chodrosarcoma
Keynote Speakers
Department of Health Science, University “Magna Graecia” Medical School, Digestive Surgery Unit, "Renato Dulbecco" Hospital, Viale Europa, Germaneto, 88100 Catanzaro, Italy
Prof. Michele Ammendola is an Associate Professor of General Surgery. Author of many scientific articles published in international journals with international collaborations. Member of International Scientific Societies. His ongoing research interests involve the study of tumor microenvironment, particularly analyzing the role of immune stromal cells in neoangiogenesis of gastrointestinal solid tumors (Study of the mechanisms of remodeling of the tumor microenvironment in colorectal tumors, Principal Investigator in the PRIN 2022 2022CMTZNH project).
President of ASMD Spain (Patients Association),
Board member of FEDER (Spanish Federation of Rare Diseases),
Board member of Eurordis (Rare Diseases Europe)
Center for Studies and Research in Cognitive Neuroscience, Department of Psychology, University of Bologna, Bologna, Italy,
Department of Psychology, University of Turin, Turin, Italy
My research experience focuses on investigating the intricate functional interplay of different brain areas involved in emotional learning, action control, brain plasticity, decision-making, and a variety of cognitive tasks. To this end, my research activities primarily revolve around the utilization of non-invasive brain stimulation techniques such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), in addition to employing various neuroscientific techniques to record physiological measures, including EEG, SCR, HRV, and EMG. I have conducted extensive research involving both healthy individuals, examining intra/inter-individual differences, and patients with acquired brain injuries. In my investigations, I employ a multimodal approach that integrates behavioral assessments, electrophysiological measurements, and neurostimulation techniques. The overarching aim of my research is to develop innovative therapeutic protocols, with a particular focus on utilizing the cortico-cortical paired associative stimulation (ccPAS) method to facilitate neuroplasticity and enhance functional recovery. Recently, in 2023, I was recognized as one of the world's top 2% scientists by Stanford University and Elsevier, and in 2024, I won the 'Young Investigator Award' granted by the European Society for Cognitive and Affective Neuroscience (ESCAN).
Cognitive Processes; Neuroinflammation; Tryptophan-Kynurenine Pathway; NMDA Receptors; Noradrenergic System; Endocannabinoid Signaling; Oxidative Stress; Antioxidants; Neurodegeneration; Neuropsychology
Department of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases—IRCAD, University of Eastern Piedmont, 28100 Novara, Italy.,
Center for Translational Research on Autoimmune and Allergic Disease—CAAD, Università del Piemonte Orientale, 28100 Novara, Italy
From data to diagnosis: biomarker discovery in amyotrophic lateral sclerosis
Sessions
S2. Immunotherapy and Adverse Effects
S3. Tumor Microenvironment
S4. Immune System, Tumor Immunology and Autoimmune Disease
S5. Biomedicine in Cardiovascular Diseases
S6. Diabetes, Obesity and Metabolic Diseases
S7. Gene Therapy and Gene Editing
S8. Rare Diseases
S9. Molecular Mechanisms of Neurodegeneration
Registration
When registering, please register with your academic email address, as this will accelerate the registration process. If you are registering several people under the same registration, please do not use the same email address for each person, but their individual university email addresses. Thank you for understanding.
The number of participants is limited; once the number of registrations reaches the maximum number of participants, another registration will be cancelled.
Finally, only registered authors will be able to apply for the Conference Awards.
Instructions for Authors
The 3rd International Electronic Conference on Biomedicines will accept abstracts only. The accepted abstracts will be available online on Sciforum.net during and after the conference.
1. Deadline for abstract submission: 19 January 2025 .
2. Abstract Acceptance Notification: 19 February 2025. You will be notified of the acceptance of an oral/poster presentation in a separate email.
Abstract submissions should be completed online by registering with www.sciforum.net and using the "New Submission" function once logged into the system. No physical template is necessary.
1. The structure abstract should include the introduction, methods, results, and conclusions sections of about 250–300 words in length.
2. All accepted abstracts will be published in the conference report of The 3rd International Electronic Conference on Biomedicines in Medical Sciences Forum Journal (ISSN 2673-9992); if you wish to publish an extended proceeding paper (5-9 pages), please submit it to the same journal after the conference.
3. All abstracts should be submitted and presented in clear, publication-ready English with accurate grammar and spelling.
4. You may submit multiple abstracts. However, only one abstract will be selected for oral presentation.
5. All abstracts accepted for presentation will be collected in a book of abstracts, which will be published on the website after the conference.
Detailed Requirements:
1. The submitting author must ensure that all co-authors are aware of the contents of the abstract.
2. Please select only one presenter for each submission. If you would like to change the presenter after submission, please email us accordingly.
Note: We only accept live presentations.
The slot for the oral presentation is 15 mins. We advise that your presentation lasts for a maximum of 12 mins, leaving at least 3 mins for the Q&A session. Authors are encouraged to prepare a presentation in PowerPoint or similar software.
a. Your submission should include the title, authors, contact details, and main research findings, as well as tables, figures, and graphs where necessary.
b. File format: PDF (.pdf).
c. Size in cm: 60 width x 80 height–portrait orientation.
d. Font size: ≥20.
e. Maximum size: 250 M
You can use our free template to create your poster. The poster template can be downloaded here.
The Poster Sessions will take place in Zoom break-out rooms. The rooms will be called after your surname. You will automatically be assigned to your break-out room, however, you will be responsible for your own room, i.e. sharing your screen by yourself, handling the comments in the chat if there are any, etc. People will then be able to visit your room and discuss your poster with you. Please make sure you have the Zoom Desktop client or mobile app, version 5.3.0 or higher.
We will reach out to you closer to the dates of the conference with more information.
It is the authors' responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state "The authors declare no conflicts of interest." This should be conveyed in a separate "Conflict of Interest" statement preceding the "Acknowledgments" and "References" sections at the end of the manuscript. Any financial support for the study must be fully disclosed in the "Acknowledgments" section.
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe authors should retain the copyright to their scholarly works. Hence, by submitting an abstract to this conference, you retain the copyright to the work, but you grant MDPI the non-exclusive right to publish this abstract online on the Sciforum.net platform. This means you can easily submit your full paper (with the abstract) to any scientific journal at a later stage and transfer the copyright to its publisher if required.
Publication Opportunities
1. Biomedicines Journal Publication
Participants in this conference are cordially invited to contribute a full manuscript to the conference's Special Issue, published in Biomedicines (ISSN: 2227-9059, Impact Factor 3.9), with a 20% discount on the publication fee. Details of the special issue will be announced here later. Please note that no other discounts are applicable. All submitted papers will undergo MDPI’s standard peer-review procedure. The abstracts should be cited and noted on the first page of the paper.
2. Proceeding Paper Publication
You are welcome to submit a proceeding paper (5-9 pages) to Medical Sciences Forum Journal (ISSN 2673-9992) after the conference. Publication of the proceedings will be free of charge. Authors are asked to disclose that it is a proceeding paper of the ECB 2025 conference paper in their cover letter. Please submit your manuscript from 15 May to 31 June 2025. Carefully read the rules outlined in the 'Instructions for Authors' on the journal’s website and ensure that your submission adheres to these guidelines.
Manuscripts for the proceedings issue must be formatted as follows:
-
Title.
-
Full author names.
-
Affiliations (including full postal address) and authors' e-mail addresses.
-
Abstract.
-
Keywords.
-
Introduction.
-
Methods.
-
Results and Discussion.
-
Conclusions.
-
Acknowledgements.
-
References.
Event Awards
To acknowledge the support of the conference's esteemed authors and recognize their outstanding scientific accomplishments, we are pleased to announce that the conference will provide six awards including Best Oral Presentation Awards and Best Poster Awards.
The Awards
Number of Awards Available: 6
The Best Oral Presentation Awards are given to the submission judged to make the most significant oral contribution to the conference.
The Best Poster Awards are given to the submission judged to make the most significant and interesting poster for the conference.
There will be six winners selected for these awards. The winner will receive a certificate and 200 CHF each.
Conference Secretariat
Ms. Yachne Yu
Ms. Alethea Liu
Ms. Suriwipa Chuachaina
Email: ecb@mdpi.com
For inquiries regarding submissions and sponsorship opportunities, please feel free to contact us.
S1. Insulin Resistance or Hyperinsulinemia
Despite the large amount of scientific literature supporting the fact that insulin resistance with associated hyperinsulinemia is an independent risk factor for the development of type 2 diabetes mellitus, cardiovascular disease, cancer, cellular senescence, and cognitive impairment/dementia, it still today it is not screened in the general population and treated preventively. This session aims to stimulate the scientific community on the topic, collecting the most recent scientific knowledge from both an experimental and clinical point of view.
Keywords: Insulin Resistance, Hyperinsulinemia, Insulin Signaling, Risk Factor, Type 2 Diabetes Mellitus, Cardiovascular Disease, Cancer, Cellular Senescence, Cognitive Impairment, Dementia, Alzheimer’s Disease
Session Chair
Prof. Dr. Serafino Fazio, Retired Professor of Internal Medicine, Federico II University School of Medicine, Naples, Italy
S2. Immunotherapy and Adverse Effects
The session encourages innovative, multidisciplinary research in immunotherapy and autoimmune adverse effects. As immunotherapy advances cancer treatment, autoimmune adverse effects have increased. This session will explore the molecular mechanisms, the latest management strategies, and digital health's role in monitoring and predicting these reactions. Additionally, we will discuss how precision health approaches can tailor treatments to individual patient profiles, minimizing risks while maximizing therapeutic benefits. Join us to bridge cutting-edge science with practical solutions to enhance patient outcomes in immunotherapy.
Keywords: Immunotherapy, Autoimmune Adverse Effects, Digital Health, Precision Health, Patient Monitoring, Personalized Medicine, Adverse Reaction Management, Treatment Optimization
Session Chair
Dr. Allan Stensballe, Laboratory for Medical Mass Spectrometry, Biomedicine group, Aalborg University, Aalborg, Denmark
S3. Tumor Microenvironment
The tumor microenvironment (TME) significantly impacts cancer progression through a complex interplay with tumor cells. The main mechanisms include immune evasion, recruitment of pro-tumorigenic cells, angiogenesis, and extracellular matrix remodeling. The therapeutic interventions further refine the TME, often promoting resistance to anti-cancer therapy. Understanding the dynamic nature of the TME is essential for developing effective therapies targeting TME. This session aims to provide an opportunity for a diverse group of scientists to participate in a discussion on a comprehensive update on recent TME research.
Keywords: Tumor Microenvironment, Tumor Microenvironment Targeting, Tumor Microenvironment Modulation, Angiogenesis, Cancer Cell Interactions, Extracellular Matrix, Cancer Therapy
Session Chair
Prof. Dr. Georgia Levidou, Department of Pathology, Paracelsus medical university, Klinikum Nuremberg, Germany
S4. Immune System, Tumor Immunology and Autoimmune Disease
Immune responses play a pivotal role in the development and perpetuation of human disorders, including cancer and autoimmune diseases. Deciphering the involvement of key immune pathogenetic mechanisms paves the way for the identification of new therapeutic targets as well as novel biomarkers for prognoses and responses to therapy. The session encourages innovative, multidisciplinary, basic, preclinical, and clinical research on cutting-edge aspects of tumor immunology and autoimmune disorders, aiming at the improvement of patients’ survival rates and quality of life.
Keywords: antitumor immunity; autoinflammatory reactions; immunotherapy; biomarkers; state-of-the-art methods
Session Chairs
Dr. Maria-Ioanna (Marianna) Christodoulou, 1. Department of Life Sciences, European University Cyprus, Nicosia 2404, Cyprus 2. School of Infection and Immunity, University of Glasgow, Glasgow G12 8TA, UK
Dr. Giuseppe Cappellano, Department of Health Sciences, Center for Translational Research on Autoimmune and Allergic Disease-CAAD, Università del Piemonte Orientale, 28100 Novara, Italy
S7. Gene Therapy and Gene Editing
"Gene Therapy and Gene Editing" is a groundbreaking field that delves into the manipulation of genes to treat or prevent diseases. This session will scrutinize the cutting-edge techniques and ethical considerations in gene editing, including CRISPR-Cas9 and other novel approaches. We will dissect the scientific intricacies, clinical applications, and potential implications for medicine and society. By examining the latest research and breakthroughs, we aim to foster a comprehensive understanding of how gene therapies and gene editing technologies are revolutionizing the treatment of genetic disorders and other diseases. Join us to engage in a discourse that charts the future of genetic medicine and its profound impact on healthcare.
Keywords: gene therapy, gene editing, CRISPR-Cas9, RNA, gene vector, genetic disorders, ethical considerations
Session Chair
Dr. Songwei Tan, School of Pharmacy, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China
S8. Rare Diseases
This session will explore various perspectives on rare diseases, including: (1) the diagnostic odyssey, the roles of clinicians and molecular specialists, and screening programs and techniques; (2) treatment options, the impact of deploying novel specific therapies, and the roles of both large and small pharmaceutical companies; (3) the patient experience, the influence of patient registries, and the role of patients’ associations in shaping biomedical policy within public and private health systems.
Keywords: diagnostic odyssey, newborn screening, high-throughput omics techniques, orphan drugs, gene therapy, patient registries, patients’ associations.
Session Chair
Dr. Francisco J. del Castillo, 1. Servicio de Genética, Hospital Universitario Ramón y Cajal - IRYCIS, Madrid, Spain 2. Unit 728, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
S9. Molecular Mechanisms of Neurodegeneration
The "Molecular Mechanisms of Neurodegeneration" session explores the intricate processes underlying neurodegenerative diseases. Delve into the potential of herbal compounds in neuroprotection, understand brain-peripheral dynamics in animal models of cognitive decline, and discover cutting-edge non-invasive brain stimulation techniques, among others. The session discusses the molecular mechanisms driving neurodegeneration, providing insights into potential treatments and therapeutic strategies. Join us for a comprehensive overview of current and emerging research in this field.
Session Chair
Dr. Masaru Tanaka, HUN-REN-SZTE Neuroscience Research Group, Hungarian Research Network, University of Szeged (HUN-REN-SZTE), Szeged, Hungary